Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

Business Wire September 21, 2015

Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16

Business Wire September 15, 2015

Gilead Prices $10 Billion of Senior Unsecured Notes

Business Wire September 9, 2015

Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9

Business Wire September 8, 2015

Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study

Business Wire September 2, 2015

Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine

Business Wire August 26, 2015

European Medicines Agency Validates Gilead's Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment

Business Wire August 20, 2015

Gilead Sciences Announces Third Quarter 2015 Dividend

Business Wire July 28, 2015

Gilead Sciences Announces Second Quarter 2015 Financial Results

Business Wire July 28, 2015

Big Pharma Update: Merck (MRK) profit slashed in Q2 as Pfizer (PFE) sales soar

Canadian Press July 28, 2015

Gilead Announces Executive Promotions

Business Wire July 27, 2015

Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015

Business Wire July 21, 2015

Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)

Business Wire July 21, 2015

Japan's Ministry of Health, Labour and Welfare Approves Gilead's Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Business Wire July 3, 2015

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)

Business Wire July 1, 2015

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9

Business Wire June 8, 2015

Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia

Business Wire May 31, 2015

European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment

Business Wire May 28, 2015

Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28

Business Wire May 27, 2015

Gilead cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton

Canada NewsWire May 27, 2015